 In this ascending multiple dose, double blind, placebo controlled study, a total of 40 subjects will be randomized into 5 cohorts. Approximately 24 HS will be randomized into 3 cohorts A1, A2, and A3, and 16 migraine patients will be randomized into 2 cohorts B1 and B2. Each subject will receive a total of 3 SC doses of AMG 334 or placebo. 